Related Experiment Video
Updated: Aug 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The benefits of statin therapy--what questions remain?
Antonio M Gotto1, John C LaRosa
1Weill Medical College of Cornell University, Olin Hall, Room 205, 445 East 69th Street, New York, NY 10021, USA. amg_editorial@med.cornell.edu
Insights
Early statin trials established benefits for secondary prevention of coronary heart disease (CHD). Recent studies continue to expand understanding of statin therapy for diverse patients and lipid management.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Early hydroxymethylglutaryl-CoA reductase inhibitor (statin) trials demonstrated efficacy in secondary prevention of coronary heart disease (CHD).
- Subsequent trials with various statins have broadened the understanding of their benefits across wider patient groups.
Purpose of the Study:
- To review the evolution of statin therapy research.
- To highlight ongoing investigations into lipid-lowering goals, special populations, and surrogate markers for CHD.
Main Methods:
- Review of outcomes data from early and recent clinical trials.
- Analysis of current research trends in statin therapy and lipidology.
Main Results:
- Statins are proven effective for secondary CHD prevention.
- Expanded evidence supports statin use in diverse patient populations.
Conclusions:
- Early statin trials laid the groundwork for current knowledge.
- Ongoing research aims to refine lipid management strategies and CHD prevention through statin therapy.
Abstract:
Early hydroxymethylglutaryl-CoA reductase inhibitor (statin) trials provided the first evidence of the benefits of statin therapy in secondary prevention of coronary heart disease (CHD). Outcomes data from more recent trials involving atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin, have since expanded the patient population shown to benefit from statin therapy. Current studies are evaluating the benefits of lowering lipid levels with statins to below current goals, as well as examining benefits in special patient populations and evaluating the value of surrogate markers of CHD. Early trials provided a solid foundation of knowledge on the efficacy and safety of statins. Recent and ongoing trials generate new data to resolve remaining questions in the fields of CHD prevention and lipidology.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis IV: Nursing Management
Coronary Artery Disease IV: Preventive Measures
Peripheral Artery Disease III: Interprofessional Care